SAB Biotherapeutics is a clinical-stage biopharmaceutical company focused on the development of proprietary immunotherapeutic fully-human polyclonal antibodies, or fully-human immunoglobulins (hIgGs), to treat and prevent diseases with significant unmet medical needs, including immune and autoimmune disorders.SAB’s novel DiversitAb™ drug development platform is based on the natural human immune system. Using transchromosomic cattle, the platform has the unique ability to produce large quantities of specifically-targeted, high-potency, hIgGs that target multiple epitopes, antigens or binding sites without human donors. We have advanced genetic engineering & antibody science to produce innovative immunotherapies, with programs in infectious, gastroenterological and respiratory diseases, and oncology.
GET INVOLVED AT THE
WORLD ANTI-MICROBIAL RESISTANCE CONGRESS